BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions
March 24, 2025
0
BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College . . . This content is for paid subscribers. Please click here to subscribe or here to log in.